Provention bio announces initiation of the phase 2a prevail-2 study of prv-3279 (cd32b × cd79 bispecific dart® molecule) in systemic lupus erythematosus (sle)

Red bank, n.j., jan. 20, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the phase 2a prevail-2 study (prv-3279 evaluation in lupus- phase 2).

PRVB Ratings Summary

PRVB Quant Ranking